OpenEvidence Raises Series A at $1 Billion Valuation to Advance AI Copilot for Doctors
OpenEvidence is transforming medical knowledge organization and application, providing real-time, AI-powered decision support for healthcare professionals.
Company Name: OpenEvidence
Location: Cambridge, MA
Industry: AI-powered medical decision support
Funding Details:
- Amount: Undisclosed (Series A)
- Valuation: $1 Billion
- Investors:
- Lead: Sequoia Capital
Purpose of Investment:
- Train next-generation medical domain-specialized Large Language Models (LLMs)
- Expand team of scientists working at the intersection of AI and medicine
- Develop strategic content partnerships to enhance medical knowledge
Leadership:
- Founder: Daniel Nadler
Product:
OpenEvidence provides an AI copilot for doctors, designed to help clinicians make high-stakes medical decisions at the point of care. The platform leverages AI-driven insights to enhance diagnostic accuracy, improve patient outcomes, and streamline clinical workflows.
About the Company:
OpenEvidence is transforming medical knowledge organization and application, providing real-time, AI-powered decision support for healthcare professionals. Already deployed in 10,000+ care centers across the United States, the company is rapidly becoming a critical tool for physicians nationwide.
Future Plans:
With this funding, OpenEvidence aims to further refine medical AI models, scale its clinical decision support capabilities, and expand adoption among healthcare providers to improve patient care outcomes.
